SG&A Spending Trends: MorphoSys AG vs. Evotec SE

In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, MorphoSys AG and Evotec SE have shown distinct patterns in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Evotec SE's SG&A expenses surged by over 840%, reflecting its aggressive expansion strategy. In contrast, MorphoSys AG experienced a more moderate increase of approximately 855%, with a notable peak in 2021.

Key Insights

• Evotec SE: Starting at just 18 million in 2014, their SG&A expenses reached a staggering 170 million by 2023, highlighting their rapid growth.
• MorphoSys AG: Despite a slower start, their expenses peaked at nearly 200 million in 2021, before stabilizing around 92 million in 2023.

These trends underscore the strategic priorities of each company, with Evotec focusing on expansion and MorphoSys on stabilization post-peak.